What you should know:
1. Dr. Blanchard has been with the company since its spin-off in July 2015. She intends to resign May 30.
2. “I’ve thoroughly enjoyed my time with SeaSpine and believe it is well-positioned to continue to innovate and take market share,” Dr. Blanchard said. “I’m proud of what we’ve built and the benefits we provide to surgeons and their patients.”
3. Ms. Commins-Tzoumakas is 21st Century Oncology’s CEO.
4. Ms. Gaeta is Establishment Labs Holdings’ CFO.
More articles on devices:
4 thoughts on spine technology evolution—Precision cutting, data analytics & more
Dr. Michael Goldsmith: How robotics and biologics are changing the spine field
Where pediatric spine would benefit from more data: 2 Qs with Dr. John Anderson
